U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H36O4
Molecular Weight 448.5937
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALGESTONE ACETOPHENIDE

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1(O[C@@](C)(O2)C6=CC=CC=C6)C(C)=O

InChI

InChIKey=AHBKIEXBQNRDNL-FVCOMRFXSA-N
InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1

HIDE SMILES / InChI
Molecular Formula C29H36O4
Molecular Weight 448.5937
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Algestone acetophenide, also known as dihydroxyprogesterone acetophenide, is an agonist of the progesterone receptor. Algestone acetophenide in combination with estradiol enanthate is sold under the brand name Deladroxate as a form of long-lasting injectable birth control. The combination provides simultaneously prolonged progestational and estrogenic activities both of which are maintained at effective levels for approximately three weeks after the intramuscular injection of a single dose.

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8429
Deladroxate

Approved Use

Combined Injectable Contraceptive
PubMed

PubMed

TitleDatePubMed
OVULATION INHIBITION WITH A LONG-ACTING PARENTERAL PROGESTOGEN-ESTROGEN COMBINATION.
1964 Nov-Dec
DELADROXATE FOR THE PREVENTION OF OVULATION.
1964 Nov-Dec
Deladroxate: a one-a-month intramuscular contraceptive.
1968 Jul

Sample Use Guides

In Vivo Use Guide
On the eight day (7th-9th) after the onset of menstruation from the last ovulatory cycle, one ml.of Deladroxate (150 mg of dihydroxyprogesterone acetophenide combined with 10 mg of estradiol enanthate) was injected intramuscularly in the deltoid or gluteal region.
Route of Administration: Intramuscular
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:05:33 UTC 2023
Edited
by admin
on Fri Dec 15 15:05:33 UTC 2023
Record UNII
OL7KC2O3OT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALGESTONE ACETOPHENIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
ALGESTONE ACETOPHENIDE [MART.]
Common Name English
Algestone acetophenide [WHO-DD]
Common Name English
PREGN-4-ENE-3,20-DIONE, 16,17-((1-PHENYLETHYLIDENE)BIS(OXY))-, (16.ALPHA.(R))-
Common Name English
SQ 15,101
Code English
ALGESTONE ACETOPHENIDE [USAN]
Common Name English
ALGESTONE ACETOPHENIDE [MI]
Common Name English
(R)-16α,17-Dihydroxypregn-4-ene-3,20-dione cyclic acetal with acetophenone
Common Name English
DELADROXONE
Brand Name English
NSC-759863
Code English
SQ-15101
Code English
SO-15101
Code English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID1022891
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
NCI_THESAURUS
C90968
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
PUBCHEM
5284538
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
NSC
759863
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
SMS_ID
100000077972
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
FDA UNII
OL7KC2O3OT
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
ChEMBL
CHEMBL2105993
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
EVMPD
SUB12773MIG
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
ECHA (EC/EINECS)
246-195-8
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
CAS
24356-94-3
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
WIKIPEDIA
ALGESTONE ACETOPHENIDE
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
MESH
D000463
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
DRUG CENTRAL
797
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
MERCK INDEX
m1503
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY Merck Index
CHEBI
49327
Created by admin on Fri Dec 15 15:05:33 UTC 2023 , Edited by admin on Fri Dec 15 15:05:33 UTC 2023
PRIMARY
Related Record Type Details
Structure of GESTADIENOL ACETATE
TARGET->ANALOGUE
Structure of Progesterone
TARGET -> AGONIST
Related Record Type Details
Structure of ALGESTONE ACETOPHENIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966